{"id":63362,"date":"2026-04-16T21:53:30","date_gmt":"2026-04-16T13:53:30","guid":{"rendered":"https:\/\/flcube.com\/?p=63362"},"modified":"2026-04-16T21:53:31","modified_gmt":"2026-04-16T13:53:31","slug":"hengrui-pharmaceuticals-secures-nmpa-clinical-approval-for-hrs-7156-a-first-in-class-heart-failure-therapy-with-global-novelty","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63362","title":{"rendered":"Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"HKG: 1276\">HKG: 1276<\/a>) has announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted clinical trial approval for <strong>HRS-7156<\/strong>, a <strong>Category 1 novel drug<\/strong> for the treatment of <strong>heart failure<\/strong>. The investigational therapy, which demonstrates the ability to <strong>significantly improve cardiac function and pathological changes<\/strong>, represents a <strong>globally unprecedented mechanism of action<\/strong> with no similar products approved anywhere worldwide.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Agency<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization (Phase I initiation)<\/td><\/tr><tr><td><strong>Product Classification<\/strong><\/td><td>Category 1 drug (novel chemical entity with no prior global approval)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>HRS-7156 \u2013 first-in-class heart failure therapy<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Heart failure (all subtypes pending further specification)<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Preclinical to Phase I transition<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>No similar products approved globally \u2013 true first-in-class designation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-therapeutic-profile-amp-mechanism-of-action\">Therapeutic Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-novel-cardiac-mechanism\">Novel Cardiac Mechanism<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Effect:<\/strong> Significant improvement in cardiac function parameters<\/li>\n\n\n\n<li><strong>Pathological Impact:<\/strong> Reversal or attenuation of underlying heart failure pathology<\/li>\n\n\n\n<li><strong>Innovation Status:<\/strong> Represents a new therapeutic approach to heart failure management<\/li>\n\n\n\n<li><strong>Development Platform:<\/strong> Hengrui&#8217;s proprietary cardiovascular drug discovery platform<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-rationale\">Clinical Rationale<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Treatment Gap:<\/strong> Despite advances in heart failure management, significant unmet need remains for therapies that directly improve cardiac function and reverse pathological remodeling<\/li>\n\n\n\n<li><strong>Therapeutic Goal:<\/strong> Disease-modifying treatment rather than symptomatic management<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Broad applicability across heart failure subtypes (HFrEF, HFpEF, HFmrEF)<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Novel mechanism distinct from current standard-of-care including ACE inhibitors, ARBs, beta-blockers, SGLT2 inhibitors, and ARNIs<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-unmet-medical-need\">Market Context &amp; Unmet Medical Need<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-heart-failure-landscape\">Heart Failure Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Prevalence:<\/strong> Over 64 million patients worldwide with heart failure<\/li>\n\n\n\n<li><strong>China Burden:<\/strong> Estimated 13.7 million heart failure patients in China, with incidence rising due to aging population and improved survival from acute cardiac events<\/li>\n\n\n\n<li><strong>Mortality Rates:<\/strong> 5-year survival rate remains below 50% despite current therapies<\/li>\n\n\n\n<li><strong>Economic Impact:<\/strong> Heart failure represents one of the leading causes of hospitalization and healthcare expenditure globally<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-therapeutic-innovation-opportunity\">Therapeutic Innovation Opportunity<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-in-Class Premium:<\/strong> Novel mechanisms in cardiovascular disease command significant market premiums and rapid adoption<\/li>\n\n\n\n<li><strong>Global Commercial Potential:<\/strong> Worldwide market opportunity given universal nature of heart failure<\/li>\n\n\n\n<li><strong>Regulatory Incentives:<\/strong> Potential for expedited pathways including breakthrough therapy designation in multiple jurisdictions<\/li>\n\n\n\n<li><strong>Partnership Attractiveness:<\/strong> High-value asset for potential global licensing or co-development agreements<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-for-hengrui-pharmaceuticals\">Strategic Implications for Hengrui Pharmaceuticals<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cardiovascular Leadership:<\/strong> Establishes Hengrui as an innovator in high-need cardiovascular therapeutics beyond oncology<\/li>\n\n\n\n<li><strong>Global Ambition:<\/strong> First-in-class status positions HRS-7156 for international development and regulatory filings<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Demonstrates successful application of internal drug discovery capabilities to complex cardiovascular targets<\/li>\n\n\n\n<li><strong>Portfolio Diversification:<\/strong> Expands beyond established oncology franchise into premium cardiovascular segment<\/li>\n<\/ul>\n\n\n\n<p>&#8220;This NMPA approval for HRS-7156 marks a transformative moment for Hengrui and potentially for millions of heart failure patients worldwide,&#8221; said Dr. Sun Puyuan, Chairman and CEO of Hengrui Pharmaceuticals. &#8220;With no similar products approved anywhere globally, HRS-7156 represents a truly novel approach to addressing the fundamental pathology of heart failure, offering hope for meaningful improvement in both cardiac function and patient outcomes.&#8221;<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development plans, regulatory approvals, and therapeutic potential. Actual results may differ due to risks including clinical trial outcomes, safety findings, regulatory requirements, competitive developments, and uncertainties inherent in first-in-class drug development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600276_20260416_4TG0.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20260416_4TG0.\"><\/object><a id=\"wp-block-file--media-1d8531d4-eeeb-447e-9c56-714dc9d5c37e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600276_20260416_4TG0.pdf\">600276_20260416_4TG0<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600276_20260416_4TG0.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-1d8531d4-eeeb-447e-9c56-714dc9d5c37e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has announced that China&#8217;s National Medical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,69,2586,4228,852],"class_list":["post-63362","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-cvd","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has announced that China&#039;s National Medical Products Administration (NMPA) has granted clinical trial approval for HRS-7156, a Category 1 novel drug for the treatment of heart failure. The investigational therapy, which demonstrates the ability to significantly improve cardiac function and pathological changes, represents a globally unprecedented mechanism of action with no similar products approved anywhere worldwide.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63362\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has announced that China&#039;s National Medical Products Administration (NMPA) has granted clinical trial approval for HRS-7156, a Category 1 novel drug for the treatment of heart failure. The investigational therapy, which demonstrates the ability to significantly improve cardiac function and pathological changes, represents a globally unprecedented mechanism of action with no similar products approved anywhere worldwide.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63362\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-16T13:53:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-16T13:53:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63362#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63362\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty\",\"datePublished\":\"2026-04-16T13:53:30+00:00\",\"dateModified\":\"2026-04-16T13:53:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63362\"},\"wordCount\":535,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CVD\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63362#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63362\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63362\",\"name\":\"Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-16T13:53:30+00:00\",\"dateModified\":\"2026-04-16T13:53:31+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has announced that China's National Medical Products Administration (NMPA) has granted clinical trial approval for HRS-7156, a Category 1 novel drug for the treatment of heart failure. The investigational therapy, which demonstrates the ability to significantly improve cardiac function and pathological changes, represents a globally unprecedented mechanism of action with no similar products approved anywhere worldwide.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63362#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63362\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63362#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has announced that China's National Medical Products Administration (NMPA) has granted clinical trial approval for HRS-7156, a Category 1 novel drug for the treatment of heart failure. The investigational therapy, which demonstrates the ability to significantly improve cardiac function and pathological changes, represents a globally unprecedented mechanism of action with no similar products approved anywhere worldwide.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63362","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has announced that China's National Medical Products Administration (NMPA) has granted clinical trial approval for HRS-7156, a Category 1 novel drug for the treatment of heart failure. The investigational therapy, which demonstrates the ability to significantly improve cardiac function and pathological changes, represents a globally unprecedented mechanism of action with no similar products approved anywhere worldwide.","og_url":"https:\/\/flcube.com\/?p=63362","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-16T13:53:30+00:00","article_modified_time":"2026-04-16T13:53:31+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63362#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63362"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty","datePublished":"2026-04-16T13:53:30+00:00","dateModified":"2026-04-16T13:53:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63362"},"wordCount":535,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","CVD","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63362#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63362","url":"https:\/\/flcube.com\/?p=63362","name":"Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-16T13:53:30+00:00","dateModified":"2026-04-16T13:53:31+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has announced that China's National Medical Products Administration (NMPA) has granted clinical trial approval for HRS-7156, a Category 1 novel drug for the treatment of heart failure. The investigational therapy, which demonstrates the ability to significantly improve cardiac function and pathological changes, represents a globally unprecedented mechanism of action with no similar products approved anywhere worldwide.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63362#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63362"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63362#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63362"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63362\/revisions"}],"predecessor-version":[{"id":63366,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63362\/revisions\/63366"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}